Morphic Medical Welcomes New CEO Amid Growth Strategy
Morphic Medical, a pioneering company in the MedTech space, is making waves by announcing a significant leadership transition that reflects its ongoing evolution and ambitious growth path. They focus on minimally invasive treatments for obesity and cardiometabolic disorders, aiming to enhance patient care and accessibility.
Leadership Transition at Morphic
After five years of dedicated service, Joe Virgilio is stepping down as Chief Executive Officer of Morphic Medical. His tenure has been marked by remarkable achievements in product development, manufacturing improvements, and overall company growth. Notably, under his guidance, the company achieved key regulatory approvals that have propelled its innovative therapies forward.
Effective immediately, Mike Gutteridge, who previously served as the company’s Vice President of Therapy Development and Commercial Operations, will take on the CEO role. His notable experience in the bariatric endoscopy sector positions him well to drive Morphic Medical into its next chapter. Mike's substantial expertise in crafting go-to-market strategies specifically for the RESET therapy highlights preparations for a robust market presence.
Vision for the Future
Reflecting on this transition, Mark Lerdal, Chair of the Board of Directors, expressed gratitude for Joe Virgilio's leadership, highlighting his instrumental role in shaping the company's direction. Mark also extended a warm welcome to Mike Gutteridge, emphasizing his strong alignment with the company’s foundational values and his successful history in international commercialization.
Continued Commitment to Innovation
As Joe Virgilio noted, “It has been a privilege to lead Morphic Medical over the past five years.” His confidence in the team and commitment to the company’s mission are clear as he transitions into a supportive role following this leadership change. This new chapter is underscored by Gutteridge's passion for building upon Morphic’s legacy of innovation in the gastrointestinal metabolic health field.
Looking Ahead with Confidence
Mike Gutteridge expressed his enthusiasm for his new responsibilities, noting the importance of leveraging Morphic's pioneering work in GI metabolic health as a foundation for future endeavors. His commitment to fostering a culture rich in agility, purpose, and partnership is integral to the company's strategy moving forward.
The leadership transition will be managed thoughtfully over the coming months to ensure seamless operations and maintain strong relationships with stakeholders and partners alike. Mike’s focus will be broadening the global market presence, expediting the commercialization process, and deepening the commitment to patient well-being through effective and durable therapies.
About Morphic Medical
Morphic Medical stands out as the developer of RESET, an innovative endoscopically delivered therapy designed to provide a non-surgical alternative for individuals suffering from morbid obesity and concurrent cardiometabolic risk factors, including type 2 diabetes and dyslipidemia. It’s crucial to note that RESET is not approved for sale domestically and is currently for investigational use only.
Founded in 2003 and headquartered in Boston, Massachusetts, Morphic Medical remains at the forefront of medical innovation. The company continues to drive forward with exciting developments aimed at improving patient outcomes. For additional updates, Morphic invites interested parties to follow them on social media platforms and stay engaged with ongoing developments.
Frequently Asked Questions
Who is the new CEO of Morphic Medical?
The new CEO is Mike Gutteridge, who has previously served as the Vice President of Therapy Development and Commercial Operations.
What did Joe Virgilio accomplish as CEO?
Joe Virgilio led Morphic Medical through significant milestones in product development and regulatory approvals, shaping it into a leader in MedTech.
What is the focus of Morphic Medical?
Morphic Medical focuses on minimally invasive treatments for obesity and related cardiometabolic disorders.
How is Morphic planning to expand under new leadership?
Morphic plans to expand into global markets, accelerate commercialization, and deepen its commitment to patient care under Mike Gutteridge’s leadership.
What is RESET?
RESET is Morphic Medical’s endoscopically delivered therapy, providing a non-surgical option for those with morbid obesity and associated conditions.
